Association between CYP2C19 polymorphism and proton pump inhibitors adverse drug reactions: a narrative review
Proton pump inhibitors (PPIs) are widely prescribed medications for the management of acid-related disorders, due to their effectiveness and favorable pharmacokinetics. However, the occurrence and severity of adverse drug reactions (ADRs) in patients using PPIs, particularly in relation to their ass...
Saved in:
Main Authors: | Asmaa Ibrahim, Kazeem Yusuff, Ahmed Awaisu, Hazem Elewa |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-02-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1523399/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Gastroesophageal reflux disease, resistant to proton pump inhibitors
by: V. O. Kaybysheva, et al.
Published: (2011-06-01) -
CYP2C19 Genotype‐Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional Procedure
by: Kayla R. Tunehag, et al.
Published: (2025-01-01) -
Change in Symptoms and Mucosal Findings after Proton Pump Inhibitor in Patients with Laryngopharyngeal Reflux
by: Min Woo Park, et al.
Published: (2025-01-01) -
Proton pump inhibitors enhance chemosensitivity, promote apoptosis, and suppress migration of breast cancer cells
by: Ihraiz Worood G., et al.
Published: (2020-06-01) -
Deprescribing and Optimal Selection of Proton Pump Inhibitors (Contributions of the 26th United Russian Gastroenterology Week)
by: V. T. Ivashkin, et al.
Published: (2020-12-01)